NO20051471L - Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser - Google Patents

Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser

Info

Publication number
NO20051471L
NO20051471L NO20051471A NO20051471A NO20051471L NO 20051471 L NO20051471 L NO 20051471L NO 20051471 A NO20051471 A NO 20051471A NO 20051471 A NO20051471 A NO 20051471A NO 20051471 L NO20051471 L NO 20051471L
Authority
NO
Norway
Prior art keywords
dione
stress
treatment
dimethylpiperidine
pamoate
Prior art date
Application number
NO20051471A
Other languages
English (en)
Inventor
Camille Georges Wermuth
Original Assignee
Prestwick Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestwick Pharmaceuticals Inc filed Critical Prestwick Pharmaceuticals Inc
Publication of NO20051471L publication Critical patent/NO20051471L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nye pamoatsalter av visse 3-fenyl-3-dimetylaminoalkyl-4,4-dimetylpiperidin-2,6-dion med formel 1,. og farmakologisk akseptable solvater. derav er uten vekttap og. heopatocyttforandringer hos rotter som. begrenset de marginalt effektive. nivåene til de godkjente kliniske dosene. av de korresponderende hydrokloridene. ved behandling eller profylakse av. stressrelaterte affektforstyrrelser slik. som angst, depresjon, migrene og. søvnapné.Nye pamoatsalter av visse 3-fenyl-3-dimetylaminoalkyl-4,4-dimetylpiperidin-2,6-dion med formel I:. og farmakologisk akseptable solvater derav er uten vekttap og heopatocyttforandringer hos rotter som begrenset de marginalt effektive nivåene til de godkjente kliniske dosene av de korresponderende hydrokloridene ved behandling eller profylakse av stressrelaterte affektforstyrrelser slik som angst, depresjon, migrene og søvnapnoea. Foretrukne pamoatsalter er 3(3,5-dimetoksyfenyl)-3-(3-dimetylaminopropyl)-4,4-dimetylpiperidin-2,6-dionpamoat, og særlig 3(3-metoksyfenyl)-3-(3-dimetylamino-propyl)-4,4-dimetylpiperidin-2,6-dionpamoat
NO20051471A 2002-08-22 2005-03-21 Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser NO20051471L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219639.2A GB0219639D0 (en) 2002-08-22 2002-08-22 Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
PCT/IB2003/003698 WO2004017970A1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders

Publications (1)

Publication Number Publication Date
NO20051471L true NO20051471L (no) 2005-05-23

Family

ID=9942831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051471A NO20051471L (no) 2002-08-22 2005-03-21 Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser

Country Status (23)

Country Link
US (2) US7514454B2 (no)
EP (1) EP1539160B1 (no)
JP (1) JP2005538146A (no)
KR (1) KR20050038014A (no)
CN (1) CN1678316A (no)
AT (1) ATE330605T1 (no)
BR (1) BR0313674A (no)
CA (1) CA2495377A1 (no)
CY (1) CY1105541T1 (no)
DE (1) DE60306396T2 (no)
DK (1) DK1539160T3 (no)
EA (1) EA007900B1 (no)
ES (1) ES2268474T3 (no)
GB (1) GB0219639D0 (no)
GE (1) GEP20074051B (no)
IL (1) IL166941A (no)
MX (1) MXPA05001919A (no)
NO (1) NO20051471L (no)
NZ (1) NZ538341A (no)
PL (1) PL373416A1 (no)
PT (1) PT1539160E (no)
UA (1) UA80144C2 (no)
WO (1) WO2004017970A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
GB0518763D0 (en) * 2005-09-14 2005-10-19 Prestwick Pharmaceuticals Inc Treatment of hypertension
BRPI0702900A2 (pt) * 2006-06-28 2011-03-15 Teva Pharma formas cristalinas da atorvastatina
BR112014024833B1 (pt) 2012-04-04 2022-10-04 Intervet International B.V. Produto farmacêutico veterinário mastigável macio, processo para sua fabricação e seu uso, bem como uso de pamoato de sódio
CN105727117A (zh) * 2016-02-03 2016-07-06 瓮杰林 一种治疗前列腺增生的药物及其制备方法
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
CN115702894A (zh) * 2021-08-11 2023-02-17 朱信红 一种用于止吐的缓释组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1455687A (en) * 1972-12-28 1976-11-17 Aspro Nicholas Ltd Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
EP0216555B1 (en) * 1985-09-11 1992-09-02 Btg International Limited Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
DE3779991T2 (de) 1986-09-08 1993-02-04 British Tech Group Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
GB8716338D0 (en) 1987-07-10 1987-08-19 Nat Res Dev Anti-anxiogenic compositions
GB2379216A (en) * 2001-08-28 2003-03-05 Maurice Ward Gittos Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders

Also Published As

Publication number Publication date
DK1539160T3 (da) 2006-10-09
MXPA05001919A (es) 2005-06-03
CA2495377A1 (en) 2004-03-04
US7514454B2 (en) 2009-04-07
CY1105541T1 (el) 2010-07-28
EA200500242A1 (ru) 2005-08-25
DE60306396D1 (de) 2006-08-03
PT1539160E (pt) 2006-10-31
US20060025443A1 (en) 2006-02-02
IL166941A (en) 2010-04-15
ES2268474T3 (es) 2007-03-16
KR20050038014A (ko) 2005-04-25
NZ538341A (en) 2006-09-29
GEP20074051B (en) 2007-02-26
GB0219639D0 (en) 2002-10-02
EA007900B1 (ru) 2007-02-27
US20090182012A1 (en) 2009-07-16
CN1678316A (zh) 2005-10-05
AU2003255947A1 (en) 2004-03-11
WO2004017970A1 (en) 2004-03-04
EP1539160B1 (en) 2006-06-21
PL373416A1 (en) 2005-08-22
EP1539160A1 (en) 2005-06-15
DE60306396T2 (de) 2007-05-03
JP2005538146A (ja) 2005-12-15
ATE330605T1 (de) 2006-07-15
UA80144C2 (uk) 2007-08-27
BR0313674A (pt) 2005-06-21

Similar Documents

Publication Publication Date Title
NO20051471L (no) Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser
NO20063928L (no) Substituerte kinolinforbindelser
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
NO20161634A1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20070588L (no) Piperidinderivater som NK1-antagonister.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20021781L (no) Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase
NO20071193L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
KR20010102040A (ko) 아미드 화합물 및 그 의약으로서의 용도
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20042141L (no) Terapeutiske quinolonforbindelser med 5-HT-antagonistiske egenskaper
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
BR0206513A (pt) Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
IL160615A0 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application